Securities code: 688278 Securities abbreviation: Tebao Biotechnology Announcement No.: 2025-005

Xiamen Tebao Bioengineering Co., Ltd

2024 Annual Results Bulletin Announcement

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

The main financial data for 2024 contained in this announcement are preliminary accounting data and have not been audited by an accounting firm

The specific data is subject to the data disclosed in the 2024 annual report of Xiamen Tebao Bioengineering Co., Ltd. (hereinafter referred to as the "Company"), and investors are reminded to pay attention to investment risks.

1. Main financial data and indicators for 2024

Unit: 10,000 yuan

Item Current reporting period Same period last year Change (%)

Total operating income 281,715.82 210,032.29 34.13

Operating profit 97,073.66 68,072.05 42.60

Total profit 93,102.66 64,065.45 45.32

Attributable to parent company 82,760.22 55,544.94 49.00

net profit of the company

Vested in the parent company

Non-recurring deductions 82,696.48 57,939.00 42.73

Net profit from profit or loss

Basic earnings per share (RMB) 2.03 1.37 48.18

Weighted average net assets 37.74 33.98 11.07

Yield

End of the reporting period Beginning of the reporting period Change of change (%)

Total assets 305,041.48 235,608.71 29.47

All attributable to the parent company 255,331.63 187,640.13 36.08

Owner's rights

Share capital 40,680.00 40,680.00 -

Vested in the parent company

Net assets per share 6.28 4.61 36.23

(RMB)

Note: 1. The beginning of the reporting period is the same as the end of the previous year as disclosed by law.

2. The above financial data and indicators are filled in with consolidated statement data, but are unaudited, and the final results are subject to the company's 2024 annual report.

2. Explanation of operating performance and financial situation

(1) The company's operating conditions, financial status and main factors affecting operating performance during the reporting period

1. The company's operating and financial status during the reporting period

During the reporting period, the company's operating performance maintained stable growth, achieving a total operating income of 2817.1582 million yuan, a year-on-year increase of 34.13%; the net profit attributable to the owners of the parent company was 827.6022 million yuan, a year-on-year increase of 49.00%; The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 826.9648 million yuan, a year-on-year increase of 42.73%.

At the end of the reporting period, the company's total assets were 3050.4148 million yuan, an increase of 29.47% over the beginning of the reporting period. ascription

The owner's equity of the parent company was 255,331.63 million yuan, an increase of 36.08% from the beginning of the reporting period.

2. The main factors affecting business performance

During the reporting period, the company's main business was stable and improving, especially with the continuous deepening of clinical cure research on hepatitis B, the company's product peggebine as a first-line drug for chronic hepatitis B antiviral treatment has been further recognized by experts and patients, and the product has continued to increase in volume, driving greater growth in operating performance.

(2) The main reasons for the increase or decrease of more than 30% of the relevant items in the above table

1. During the reporting period, the company's total operating income, operating profit, total profit, net profit attributable to the owners of the parent company, net profit attributable to the owners of the parent company after deducting non-recurring gains and losses, and basic earnings per share achieved a large increase, mainly due to the steady growth of sales revenue of key products Paigbin, and at the same time, the company promoted management reform in an orderly manner, focused on improving organizational efficiency and operational quality and efficiency, and further enhanced the overall profitability.

2. During the reporting period, the company's owner's equity attributable to the parent company and net assets per share attributable to the owners of the parent company increased significantly, mainly due to the increase in the company's net profit.

3. Risk Warning

The main financial data for 2024 contained in this report are the preliminary accounting data of the Company and have not been accounted for

The specific data of the audited are subject to the audited 2024 annual report officially disclosed by the company, and investors are advised to pay attention to the investment risks.

The announcement is hereby made.

Xiamen Tebao Bioengineering Co., Ltd

board of directors

February 26, 2025